Compliance & Medical Disclaimer

This article is for informational and educational purposes only and does not constitute medical, legal, regulatory, or professional advice. The compounds discussed are research chemicals not approved for human consumption by the US FDA, European Medicines Agency (EMA), UK MHRA, Australian TGA, Health Canada, or any other major regulatory authority. They are sold strictly for laboratory research use. WolveStack does not employ medical staff, does not diagnose, treat, or prescribe, and makes no health claims under FTC, UK ASA, EU MDR/UCPD, or AU TGA standards. Always consult a licensed healthcare professional in your jurisdiction before considering any peptide protocol. This site contains affiliate links (FTC 2023 endorsement guidelines compliant); we may earn a commission on qualifying purchases at no additional cost to you. Some compounds discussed are on the WADA prohibited list — competitive athletes should verify current status with their governing body before any research use. Use of research chemicals may be illegal in your jurisdiction.

Reviewed by: WolveStack Research Team
Last reviewed: 2026-04-28
Editorial policy

Editorial review process: WolveStack Research Team — collective expertise in peptide pharmacology, regulatory science, and research literature analysis. We synthesize peer-reviewed studies, regulatory filings, and clinical trial data; we do not provide medical advice or treatment recommendations. Content is reviewed and updated as new evidence emerges.

Medical Disclaimer

This article is for informational and educational purposes only and does not constitute medical advice. The compounds discussed are research chemicals that are not FDA-approved for human use. Always consult a licensed healthcare professional before considering any peptide protocol. WolveStack has no medical staff and does not diagnose, treat, or prescribe. See our full disclaimer.

FOXO4-DRI is administered via subcutaneous injection (5-10 mg per dose) for 3 consecutive days, repeating every 4-6 weeks. Standard injection technique uses 27-30 gauge insulin syringes into abdominal fat or upper thigh. Rotate injection sites to minimize skin irritation and ensure sterile technique throughout. Proper reconstitution with bacteriostatic water is essential for peptide stability and safety.

What Injection Sites Are Best for FOXO4-DRI?

Subcutaneous injection deposits peptide into adipose tissue below the dermis, where it absorbs gradually into circulation. Ideal sites include the abdomen (avoid navel area), upper thighs, arms, and buttocks. The abdomen is preferred for reliable absorption. Rotate sites: right abdomen → left thigh → upper arm → buttock, then repeat for next cycle. This prevents skin irritation and lipohypertrophy (thickened fat deposits from repeated injections).

Injection Technique: Depth, Angle, and Needle Insertion

Pinch and elevate subcutaneous fat, insert needle at 45-90 degrees depending on fat depth (deeper fat allows steeper angles), inject slowly over 3-5 seconds, aspirate before injecting (to check you're not in a blood vessel), then withdraw at the same angle. Standard insulin syringes (1mL, 27-30 gauge) are ideal. 30G causes minimal pain but draws slower; 27G works quickly but slightly less comfortable. Inject steadily and slowly rather than rapidly—fast injection increases local pressure and discomfort. Apply gentle pressure with sterile pad for 10-15 seconds post-injection to promote hemostasis.

Reconstitution: Water, Vials, and Preparation Protocol

FOXO4-DRI arrives as lyophilized powder. Reconstitute with sterile bacteriostatic water: 1mg peptide + 1mL water = 1mg/mL concentration. Draw water into syringe and inject slowly into vial (inject against vial wall, let water run down—never spray directly onto powder). Gently swirl until completely dissolved (takes 5-10 minutes if needed). Never shake vigorously, which denatures the peptide. Solution appears clear and colorless when ready. Store reconstituted peptide at 2-8°C; use within 2-4 weeks. Mark reconstitution date clearly on the vial.

Dosing Protocol: Cycles and Administration Schedule

Standard protocol: 5-10 mg per dose, administered for 3 consecutive days (e.g., Monday-Wednesday), then 4-6 weeks off before repeating. This 3-day-on / 28-35-day-off pattern allows senescent cell clearance during active days while permitting tissue regeneration during rest periods. Some users reduce to 3-5 mg based on tolerance or extend to 4 days. Repeat cycles indefinitely appear safe preclinically, though human long-term data is limited.

Syringe Selection and Needle Gauge

Standard 1mL insulin syringes with 28-30 gauge integrated needles are optimal. These provide precision for accurate dosing. Larger 3mL syringes (25-27 gauge) work for higher volumes. Practical approach: reconstitute to 10 mg/mL, use insulin syringes, inject 0.5-1mL per dose. Needle gauge critically affects pain—30G is dramatically more comfortable than 25G, though larger gauges draw/inject faster. A 29-30G needle is recommended for comfort.

Pain Minimization and Comfort Strategies

Subcutaneous injection pain is minimal with proper technique. Use ice packs 1-2 minutes pre-injection to numb site and vasoconstrict. Allow alcohol sterilizer to fully air-dry (30+ seconds)—wet alcohol stings intensely. Ensure reconstituted solution is room temperature; cold solutions cause more discomfort. Use smooth, confident needle insertion rather than hesitant probing. Inject slowly over 3-5 seconds—rapid injection increases discomfort. Thin-gauge needles (28-30G) are far more comfortable than larger gauges. Rotate sites to prevent irritation and calluses.

Sterility and Infection Prevention

Always use sterile, single-use syringes and needles. Sterilize vial rubber stopper with 70% alcohol, allow to air-dry before drawing. Use sterile, non-pyrogenic water for reconstitution. Critical: use one needle for drawing from vial (which dulls it), then change to fresh needle for injection. Sterilize injection site with alcohol or betadine, air-dry completely. Never reuse needles or syringes. Proper aseptic technique makes infection very unlikely. If infection develops (increasing redness, warmth, pus, fever), seek medical attention—infections can progress to cellulitis or abscess.

Common Mistakes and How to Avoid Them

Don't shake vials vigorously (denatures peptide)—use gentle swirling only. Don't use the same dull needle for drawing and injecting (increases tissue trauma)—change needles between steps. Don't inject rapidly (increases discomfort and irritation)—inject slowly over 3-5 seconds. Don't inject cold solution—allow peptide to warm to room temperature. Don't skip alcohol air-dry (causes stinging)—wait 30+ seconds. Don't over-pinch injection sites (causes bruising)—use gentle, brief pinching. Don't reuse vials or syringes (contamination risk)—always use fresh supplies. Don't skip site rotation (causes lipohypertrophy)—establish a consistent rotation pattern.

Post-Injection Care and Side Effects

Minor bleeding or bruises are normal and resolve within hours to days. Apply ice for 10-15 minutes if bleeding occurs. Avoid intense exercise for 2-4 hours post-injection to minimize local inflammation. Mild redness or soreness typically resolves within 24 hours; persistent redness beyond 2-3 days warrants checking for infection. Some users report mild systemic soreness or fatigue during injection cycles—likely immune activation from senescent cell debris clearance. Ensure adequate hydration and rest on non-injection days to minimize systemic symptoms.

Troubleshooting Common Problems

Solution won't draw: The needle is likely occluded—switch to fresh needle. Crystals in vial: Peptide degraded or contaminated water was used—discard and reconstitute with verified sterile water. Powder won't dissolve: Verify you're using bacteriostatic water, not regular water; if vial is cold, warm it gently in your hand or warm water bath (never hot—heat denatures peptides). Severe pain during injection: You may have hit a nerve—ensure proper pinching and use standard injection sites only.

Trusted Research-Grade Sources

Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).

Particle Peptides

Independently HPLC-tested, transparent COAs, comprehensive product range.

Browse Particle Peptides →

Limitless Life Nootropics

Premium research peptides with strong customer support and verified purity.

Browse Limitless Life →

Frequently Asked Questions

What gauge needle should I use?

27-30 gauge is standard. 30G insulin syringes are most common for comfort and precision. 27G works faster but slightly less comfortable. Avoid anything larger than 27G for subcutaneous injection.

Can I inject FOXO4-DRI intravenously?

Technically possible but not recommended—IV eliminates the long-acting absorption advantage of subcutaneous delivery. Most users prefer subcutaneous for sustained tissue exposure.

How deep should the needle go?

Needle should pass through skin/dermis (1-3mm) and deposit in subcutaneous fat (5-15mm deep depending on body composition). Pinch-and-inject technique naturally achieves correct depth.

What if I miss one day of the 3-day cycle?

Inject the next day at regular time. Don't double-dose. Effect is based on total 3-day exposure, not precise timing.

Can I use bacteriostatic saline instead of bacteriostatic water?

Yes, bacteriostatic saline (0.9% NaCl with benzyl alcohol) is equally acceptable. Some users prefer it for subjective comfort reasons.

How long does reconstituted FOXO4-DRI last?

Reconstituted with sterile bacteriostatic water and stored at 2-8°C, it's stable 2-4 weeks. Mark the reconstitution date and discard after 4 weeks. Some prefer smaller volumes used within 1-2 weeks for maximum stability assurance.